Exelixis Earnings Reports

Exelixis delivered strong Q4 2024 results, driven by the continued performance of the cabozantinib franchise. Total revenue reached $567 million, with net product revenue of $515.2 million. GAAP net income was $139.9 million, while non-GAAP net income was $160.3 million.

Exelixis announced strong Q3 2024 financial results with total revenues of $539.5 million and GAAP diluted EPS of $0.40. The company is increasing full year guidance for total and net product U.S. revenues due to the strong commercial performance of the cabozantinib franchise. Additionally, a favorable ruling was received on cabozantinib patent litigation, and a collaboration with Merck was expanded for the zanzalintinib development program.

Exelixis reported total revenues of $637.2 million for Q2 2024, driven by strong cabozantinib performance and a $150 million milestone payment from Ipsen. GAAP diluted EPS was $0.77, and non-GAAP diluted EPS was $0.84. The FDA accepted the sNDA for cabozantinib in advanced NET, and the company completed a $450 million stock repurchase program and announced an additional $500 million program.

Exelixis announced Q1 2024 financial results with total revenues of $425.2 million and GAAP diluted EPS of $0.12. The company is advancing its diverse pipeline and pursuing label expansion for cabozantinib.

Exelixis announced its Q4 and Fiscal Year 2023 financial results, reporting total revenues of $479.7 million for the quarter and $1.83 billion for the year. The company's GAAP diluted EPS was $0.27 for the quarter and $0.65 for the year, while non-GAAP diluted EPS was $0.33 for the quarter and $0.90 for the year. Exelixis is focused on advancing its cabozantinib franchise and pipeline development.

Exelixis announced strong Q3 2023 financial results with total revenues of $471.9 million, compared to $411.7 million for the comparable period in 2022. Net product revenues were $426.5 million, an increase from $366.5 million in the same period of the prior year. GAAP net income was $1.0 million, or $0.00 per share, while non-GAAP net income was $32.1 million, or $0.10 per share.

Exelixis announced its second quarter 2023 financial results, reporting total revenues of $469.8 million and GAAP diluted EPS of $0.25. The company highlighted the strong performance of CABOMETYX® and progress in its pipeline development, including zanzalintinib and XB002.

Exelixis announced Q1 2023 financial results with total revenues of $408.8 million and GAAP diluted EPS of $0.12. CABOMETYX® maintained its leading status in renal cell carcinoma treatment.

Exelixis reported Q4 2022 financial results, with total revenues of $423.9 million and a GAAP diluted EPS of $(0.09). The company continued to advance its cabozantinib franchise and pipeline through clinical data readouts and new collaborations.

Exelixis announced its Q3 2022 financial results, with total revenues of $411.7 million. The company's cabozantinib franchise continued to drive revenue growth, with a 39% year-over-year increase in net product revenue. Exelixis also made progress on its clinical and early-stage pipeline, including presenting detailed results from the COSMIC-313 clinical trial.

Exelixis announced its second quarter 2022 financial results with total revenues of $419.4 million and GAAP diluted EPS of $0.22. The company highlighted the 22 percent growth in cabozantinib franchise net product revenues year-over-year and key cabozantinib milestones.

Exelixis reported total revenues of $356.0 million and GAAP diluted EPS of $0.21 for the first quarter of 2022. The growth was driven by increased demand for CABOMETYX® in combination with OPDIVO® and the initial impact of the drug’s U.S. label expansion into differentiated thyroid cancer.

Exelixis announced fourth quarter and full year 2021 financial results, with total revenues of $451.1 million for the fourth quarter and $1.43 billion for the full year. The cabozantinib franchise achieved significant milestones, including $1.08 billion in U.S. net product revenues for the full year, with $302.7 million for the fourth quarter. GAAP diluted EPS was $0.29 for the fourth quarter and $0.72 for the full year. The company is also advancing its clinical pipeline and discovery programs.

Exelixis reported total revenues of $328.4 million for the quarter ended September 30, 2021, compared to $231.1 million for the comparable period in 2020. GAAP diluted EPS was $0.12 and non-GAAP diluted EPS was $0.20.

Exelixis announced a 59 percent year-over-year increase in CABOMETYX net product revenue growth and record total revenues. The company is raising its net product and total revenue guidance for 2021.

Exelixis reported total revenues of $231.1 million for the third quarter of 2020. The company is preparing to launch CABOMETYX in combination with nivolumab, pending FDA approval. Exelixis is also expanding its pipeline with XL092 and additional collaboration and license agreements.

Exelixis announced its second quarter 2020 financial results, with total revenues reaching $259.5 million. The company highlighted positive top-line results from the CheckMate -9ER study and progress in its clinical development programs.

Exelixis announced its Q1 2020 financial results, reporting total revenues of $226.9 million, which includes net product revenues of $193.9 million. GAAP diluted EPS was $0.15, and non-GAAP diluted EPS was $0.19. The company is progressing with its key corporate objectives and commercial and clinical development milestones.

Exelixis announced fourth quarter and full year 2019 financial results, reporting total revenues of $240.3 million for the quarter and $967.8 million for the full year. GAAP diluted EPS was $0.22 for the quarter and $1.02 for the full year. The company highlighted the cabozantinib franchise exceeding $1.0 billion in annual global net revenue.